Biocon and Mylan Announce Positive CHMP Opinion for Ogivri®, Biosimilar Trastuzumab

  • Posted by: Biocon Biologics

Biocon and Mylan Announce Positive CHMP Opinion for Fulphila®, Biosimilar Pegfilgrastim

  • Posted by: Biocon Biologics

Biocon Q1FY19 Revenue Rs 1,193 Cr, Up 21%; EBITDA Up 25% at Rs 307 Cr; Net Profit Up 47% at Rs 120 Cr

  • Posted by: Biocon Biologics

Kiran Mazumdar-Shaw Elected Full-Term Member of the Board of Trustees of MIT, USA

  • Posted by: Biocon Biologics

U.S. FDA Approves Mylan and Biocon’s Fulphila™ (pegfilgrastim-jmdb), the First Biosimilar to Neulasta®

  • Posted by: Biocon Biologics

Tata Memorial Hospital Team Presents Biocon’s Nimotuzumab Study Results at ASCO Annual Meeting 2018

  • Posted by: Biocon Biologics

Mylan and Biocon to Present New Data at the American Society of Clinical Oncology (ASCO) Annual Meeting Reinforcing the Efficacy, Safety and Immunogenicity of Ogivri™, the first biosimilar for Herceptin®, approved by US FDA

  • Posted by: Biocon Biologics

Biocon Update on Insulin Glargine

  • Posted by: Biocon Biologics

Biocon Q4FY18 Revenue Rs 1,237 Cr, Up 27%; EBITDA Up 30% at Rs 300 Cr; Net Profit Up 2% at Rs 130 Cr

  • Posted by: Biocon Biologics

Kiran Mazumdar-Shaw #1 Business Captain in ‘The Medicine Maker 2018 Power List’

  • Posted by: Biocon Biologics
Share